136 related articles for article (PubMed ID: 36162011)
1. Efficacy of Cytomegalovirus Specific Immunoglobulins to Reduce CMV Reactivation in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Geurten C; Ghinai R; Munford H; Lawson S
J Pediatr Hematol Oncol; 2023 Jan; 45(1):e82-e86. PubMed ID: 36162011
[TBL] [Abstract][Full Text] [Related]
2. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
4. Application of CMV-IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients.
Cui J; Zhou Y; Zhao K; Li X; Zhang H; Zhang X; Sun Y; Long B
Clin Transplant; 2024 Apr; 38(4):e15300. PubMed ID: 38555576
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis.
Gilioli A; Messerotti A; Bresciani P; Cuoghi A; Pioli V; Colasante C; Bettelli F; Giusti D; Forghieri F; Potenza L; Donatelli F; Giubbolini R; Galassi L; Marasca R; Banchelli F; D'Amico R; Pecorari M; Gennari W; Trenti T; Comoli P; Luppi M; Narni F
J Med Virol; 2021 Nov; 93(11):6292-6300. PubMed ID: 33580523
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
9. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: Experience from a Country with High Seropositivity.
Iftikhar R; Farhan M; Khan M; Chaudhry QUN; Ghafoor T; Shahbaz N; Khan MA; Khattak TA; Rehman J; Humayun S; Majeed A
Transplant Cell Ther; 2023 Aug; 29(8):521.e1-521.e7. PubMed ID: 37164292
[TBL] [Abstract][Full Text] [Related]
11. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
12. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
[TBL] [Abstract][Full Text] [Related]
13. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients.
Forlanini F; Dara J; Dvorak CC; Cowan MJ; Puck JM; Dorsey MJ
Transpl Infect Dis; 2021 Apr; 23(2):e13504. PubMed ID: 33169931
[TBL] [Abstract][Full Text] [Related]
14. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
15. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
16. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.
Jerry Teng CL; Wang PN; Chen YC; Ko BS
J Microbiol Immunol Infect; 2021 Jun; 54(3):341-348. PubMed ID: 33514495
[TBL] [Abstract][Full Text] [Related]
18. High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Lam S; Boan P; Polistena P; Cannell P; Cooney J; Wright M; Purtill D
Transpl Infect Dis; 2021 Aug; 23(4):e13633. PubMed ID: 33978289
[TBL] [Abstract][Full Text] [Related]
19. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
Junghanss C; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Little MT; Corey L; Storb R
Blood; 2002 Mar; 99(6):1978-85. PubMed ID: 11877269
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
